insulin glulisine + insulin glargine + metformin + glimepiride

This is a **fixed multi-drug combination therapy** composed of insulin glulisine (a rapid-acting insulin analog), insulin glargine (a long-acting insulin analog), metformin (a biguanide oral antihyperglycemic agent), and glimepiride (a sulfonylurea oral antihyperglycemic agent). The combination is not a branded product, but it reflects a regimen sometimes used in the management of patients with **type 2 diabetes mellitus** inadequately controlled on oral agents alone. - **Insulin glulisine** rapidly lowers blood glucose by stimulating glucose uptake in skeletal muscle and fat and inhibiting hepatic glucose output. - **Insulin glargine** provides sustained basal insulin levels for 24 hours, helping control fasting and between-meal glucose. - **Metformin** acts by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and enhancing insulin sensitivity. - **Glimepiride** increases insulin secretion from the pancreatic beta cells and may modestly enhance sensitivity to insulin. Used together, these agents provide comprehensive control of blood glucose in patients with advanced type 2 diabetes when monotherapy or dual therapy is inadequate. Evidence suggests that such combination regimens improve glycemic control significantly compared to fewer agents, without dramatically increased risk of hypoglycemia or weight gain[1][2][3][4].